| Essential medicines for universal health coverage VJ Wirtz, HV Hogerzeil, AL Gray, M Bigdeli, CP de Joncheere, MA Ewen, ... The Lancet 389 (10067), 403-476, 2017 | 639 | 2017 |
| 25 years of the WHO essential medicines lists: progress and challenges R Laing, B Waning, A Gray, N Ford, E Hoen The Lancet 361 (9370), 1723-1729, 2003 | 487 | 2003 |
| TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha E t Hoen Chi. J. Int'l L. 3, 27, 2002 | 460 | 2002 |
| Driving a decade of change: HIV/AIDS, patents and access to medicines for all E Hoen, J Berger, A Calmy, S Moon Journal of the International AIDS Society 14, 1-12, 2011 | 287 | 2011 |
| The global politics of pharmaceutical monopoly power: drug patents, access, innovation and the application of the WTO Doha Declaration on TRIPS and public health EFM t Hoen DiemenAMB, 2009 | 172 | 2009 |
| Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system? S Moon, J Bermudez, E 't Hoen PLoS Medicine 9 (5), e1001218, 2012 | 124 | 2012 |
| Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review N Ford, Z Shubber, P Saranchuk, S Pathai, N Durier, DP O'Brien, EJ Mills, ... Clinical infectious diseases 57 (9), 1351-1361, 2013 | 101 | 2013 |
| A quiet revolution in global public health: The World Health Organization’s Prequalification of Medicines Programme EFM ‘t Hoen, HV Hogerzeil, JD Quick, HB Sillo Journal of public health policy 35, 137-161, 2014 | 94 | 2014 |
| The UNITAID patent pool initiative: bringing patents together for the common good J Bermudez, E Hoen The open AIDS journal 4, 37, 2010 | 68 | 2010 |
| Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001–2016 E FM‘t Hoen, J Veraldi, B Toebes, HV Hogerzeil Bulletin of the World Health Organization 96 (3), 185, 2018 | 61 | 2018 |
| Direct-to-consumer advertising: for better profits or for better health? E Hoen American Journal of Health-System Pharmacy 55 (6), 594-597, 1998 | 50 | 1998 |
| Private patents and public health: changing intellectual property rules for access to medicines E Hoen (No Title), 2016 | 46 | 2016 |
| Global hepatitis C elimination: an investment framework A Pedrana, J Howell, N Scott, S Schroeder, C Kuschel, JV Lazarus, ... The Lancet Gastroenterology & Hepatology 5 (10), 927-939, 2020 | 43 | 2020 |
| Essential medicines are still essential AL Gray, VJ Wirtz, E FM't Hoen, MR Reich, HV Hogerzeil The Lancet 386 (10004), 1601-1603, 2015 | 38 | 2015 |
| Harmful human use of donated veterinary drug E Hoen, C Hodgkin, D Milkevicius The Lancet 342 (8866), 308-309, 1993 | 38 | 1993 |
| Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation EFM ‘t Hoen, P Boulet, BK Baker Journal of Pharmaceutical Policy and practice 10, 1-9, 2017 | 36 | 2017 |
| A pandemic treaty for equitable global access to medical countermeasures: seven recommendations for sharing intellectual property, know-how and technology K Perehudoff, E Hoen, K Mara, T Balasubramaniam, F Abbott, B Baker, ... BMJ Global Health 7 (7), e009709, 2022 | 26 | 2022 |
| Regulatory framework for access to safe, effective quality medicines L Rägo, H Sillo, E Hoen, M Zweygarth Antiviral therapy 19 (3_suppl), 69-77, 2014 | 22 | 2014 |
| Generic medicines are not substandard medicines NP Ford, E t Hoen Lancet 359 (9314), 2002 | 22 | 2002 |
| TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way from Seattle to Doha”(2002) E Hoen Chicago Journal of International Law 27, 39, 0 | 22* | |
